55
total announcements
524715.BO · 15 min delayed
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd will present long-term follow-up data on UNLOXCYT (cosibelimab-ipdl) from a prospective study in advanced cutaneous squamous cell carcinoma (aCSCC) at the ESMO Congress.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd announced that its drug UNLOXCYT (cosibelimab-ipdl) has received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) patients who are not candidates for curative surgery or curative radiation.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd will announce its second quarter results on 30 October 2026, with an earnings call scheduled for the same day at 6:30 pm IST.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has scheduled a Board Meeting on 30 October 2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 2026.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd has submitted a confirmation certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the acceptance or rejection of securities received for dematerialization during the quarter ended 30 September 2026.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd announced an update on credit ratings, with CRISIL and ICRA assigning ratings to the proposed Non-Convertible Debenture (NCD) programme and reaffirming existing ratings. The ratings reflect the company's strong business and financial profile, including its leadership position in the domestic formulations segment and robust specialty products portfolio.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of Non-Executive Independent Director.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed BSE about the cessation of a Non-Executive Independent Director.